Scholarlink

<p>The purpose of this study to isolate galactomannan from endosperm of <i>S. sesban</i> (Linn.) and <i>S. grandiflora</i> (L.) Pers. seed and examine bioactivity of galactomannan to explore therapeutic potential through in-vitro/in-silico studies, two extensively grown but therapeutic potential yet not explored. The aim is to evaluate pharmacological potential by in-vitro and in-silico studies. GPC, GC-FID, FT-IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR and HSQC were used to characterized GM and inhibitory activity against α-amylase. Average molecular weight and average molecular number were determined by GPC and found to be 3.42 × 10<sup>5</sup>, and 2.68 × 10<sup>5</sup> of SS GM respectively while 2.48 × 10<sup>5</sup> and 1.14 × 10<sup>5</sup> of SG GM respectively. M/G ratio of SS and SG GM was determined through GC-FID which consists of D-mannopyranose and D-galactopyranose with a molar ratio of 1.6: 1 and 2.1: 1 respectively. Functional groups such as OH and CH<sub>2</sub>, anomeric α, β configuration and glycosidic linkages were validated by FT-IR. In-vitro α-amylase inhibitory activity of SG GM was found to be more in comparison to SS GM. Docking study revealed that GM is identified as most lead compound against α-amylase inhibitory activity. It showed maximum binding affinity (−&#xa0;9.03 Kcal/mol) as acarbose (−&#xa0;10.5&#xa0;Kcal/mol). Thus, it has further scope to utilize as scaffold in drug design as antidiabetic agent. Hence, <i>Sesbania</i> galactomannan would be essential and beneficial for its future development and new possibilities for use in high value application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isolation and characterization of galactomannan from Sesbania seed and its inhibitory activity against α-amylase to explore its therapeutic ability

  • 期刊论文

  • 发表日期：

    2026年4月27日

查看全文
  • Shobha Singh,
  • Ritu Raj,
  • Dinesh Kumar,
  • Manjoosha Srivastava

摘要

The purpose of this study to isolate galactomannan from endosperm of S. sesban (Linn.) and S. grandiflora (L.) Pers. seed and examine bioactivity of galactomannan to explore therapeutic potential through in-vitro/in-silico studies, two extensively grown but therapeutic potential yet not explored. The aim is to evaluate pharmacological potential by in-vitro and in-silico studies. GPC, GC-FID, FT-IR, 1H NMR, 13C NMR and HSQC were used to characterized GM and inhibitory activity against α-amylase. Average molecular weight and average molecular number were determined by GPC and found to be 3.42 × 105, and 2.68 × 105 of SS GM respectively while 2.48 × 105 and 1.14 × 105 of SG GM respectively. M/G ratio of SS and SG GM was determined through GC-FID which consists of D-mannopyranose and D-galactopyranose with a molar ratio of 1.6: 1 and 2.1: 1 respectively. Functional groups such as OH and CH2, anomeric α, β configuration and glycosidic linkages were validated by FT-IR. In-vitro α-amylase inhibitory activity of SG GM was found to be more in comparison to SS GM. Docking study revealed that GM is identified as most lead compound against α-amylase inhibitory activity. It showed maximum binding affinity (− 9.03 Kcal/mol) as acarbose (− 10.5 Kcal/mol). Thus, it has further scope to utilize as scaffold in drug design as antidiabetic agent. Hence, Sesbania galactomannan would be essential and beneficial for its future development and new possibilities for use in high value application.